FKC289 / Fosun Pharma, Fosun Kairos - LARVOL DELTA

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis (clinicaltrials.gov) - P1/2 | N=32 | Not yet recruiting | Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd.

New P1/2 trial • Amyloidosis

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy (clinicaltrials.gov) - P1/2 | N=55 | Not yet recruiting | Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd.

New P1/2 trial • Glomerulonephritis • Renal Disease

SAFETY AND EFFICACY OF AUTOLOGOUS DUAL TARGETING BCMA/CD19 CAR-T FKC289 IN SUBJECTS WITH RELAPSED / REFRACTORY LIGHT CHAIN AMYLOIDOSIS (EHA 2026) - P=N/A | "All subjects were treated with daratumumab, bortezomib, cyclophosphamide and dexamethasone in the previous line, none of them had received CAR-T therapy or autologous transplantation. Figure 1. Efficacy of FKC289 in r/r ALA"

CAR T-Cell Therapy • Clinical • First-in-human • Amyloidosis • Hematological Malignancies • Renal Disease